000			03994nam a22003375i 4500
999			_c402844 _d402844
001			402844
003			ES-MaUEC
005			20240710101631.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			231127s2023 sz | fo |||| 0|eng d
020			_a9783031455865
024	7		_a10.1007/978-3-031-45586-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRL72 _b2023 EB
245	0	0	_aCOVID-19 in Dermatology _cedited by Hazel H. Oon, Chee Leok Goh
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aUpdates in Clinical Dermatology _x2523-8892
505	0		_aChapter 1. The Science of COVID-19 Disease -- Chapter 2. Cutaneous Manifestations of COVID-19 -- Chapter 3. Cutaneous Reactions to COVID-19 mRNA Vaccines -- Chapter 4. Cutaneous Reactions to non mRNA COVID-19 vaccines -- Chapter 5. Evaluation of the Patient With a Coronavirus Disease (COVID-19) Vaccine Cutaneous Reaction -- Chapter 6. Personal Protective Equipment (PPE) related Occupational Dermatoses during COVID 19 -- Chapter 7. COVID-19 OUTBREAK RESPONSE IN DERMATOLOGY -- Chapter 8. Leveraging on teledermatology in the COVID-19 pandemic -- Chapter 9. COVID-19 Dermatology Registries and the Impact of COVID-19 on Dermatology Research -- Chapter 10. Impact of COVID-19 on dermatology medical education -- Chapter 11. Management of immunosuppressed dermatology patients during COVID-19 -- Chapter 12. Therapeutic considerations of COVID-19 on aesthetic dermatology, dermatosurgery and skin cancer -- Chapter 13. Psychological aspects, sychodermatology and vaccine hesitancy during the COVID-19 pandemic -- Chapter 14. Oral COVID-19 Antiviral Agents in Dermatology Outpatient Treatment -- Chapter 15. The Economic Impact of COVID-19 on Dermatology .
520			_aSince the first cases of an acute respiratory illness were reported, the pathogen SARS-coV-2 (severe acute respiratory syndrome coronavirus 2) and its disease, COVID-19 have disrupted the world and changed the course of medical history. Clinics were under lockdown and supplies of critical drugs such as biologics and meladinine were delayed. The prolonged impact of disease has taken its toll on patients, their careers, medical staff, research and medical education. Shortly after the first landmark studies of COVID-19 vaccine trial data were made known, global mass vaccination programs were underway. Vaccine technology has expanded beyond messenger RNA (mRNA) to include non-replicating viral vectors, inactivated virus, and protein subunits. Cutaneous manifestations of vaccine reactions, including non-mRNA and their morphological patterns, indications and contraindications, vaccine global access, equity, allocation of booster doses, emerging COVID variants and subvariants, waning vaccine and treatment efficacy are the issues that begged to be explored. New oral therapies are available for treatment of COVID-19 but they bring with them drug-drug interactions and potential side effects. This book is a compilation of a concerted effort by dermatologists across the globe to join hands against COVID-19. Each chapter has been written by experts in the field, with first-hand experience and synthesized literature to offer the most up-to-date coverage in the fast-paced, changing landscape of COVID-19 in dermatology. COVID-19 in Dermatology is a valuable resource for dermatologists, dermatology residents and medical students, and general practitioners. .
988			_aSpringer_Medicine_2023
650		7	_2embne _9168912 _aPiel _xEnfermedades
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-45586-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b07/2024 _dz _ean _zSI